Movalis solution for injections 15mg 1.5ml #3

Movalis solution for injections instruction for use

You can buy Movalis solution for injections here

Movalis is a drug with anti-inflammatory, antipyretic and analgesic effect, used to treat diseases of the musculoskeletal system, such as rheumatoid arthritis, osteoarthritis, spondylitis.
Movalis is a representative of the group of nonsteroidal anti-inflammatory drugs, referring to an enolic acid derivative. It effectively relieves inflammation, eliminates pain and reduces fever. The anti-inflammatory mechanism acts on all standard models of inflammatory processes.
The mechanism of action of meloxicam due to its selective inhibitory effect on the formation of prostaglandins at the site of inflammation. This occurs as a result of selective inhibition of type 2 cyclooxygenase, an enzyme that provides prostaglandin synthesis. Unlike non-selective nonsteroidal anti-inflammatory drugs that inhibit both types of cyclooxygenase, meloxicam exhibits more therapeutic effects, while inhibition of type 1 cyclooxygenase leads to the development of more serious complications of the stomach and kidneys.
It is proved that when taking meloxicam in therapeutic doses, it does not affect platelet aggregation and bleeding time, in contrast to non-selective members of the group. When meloxicam was used, dyspeptic symptoms, vomiting, nausea, and abdominal pain developed less frequently. The frequency of perforations, ulcerative lesions and bleeding were lower and depended on the dosage of the medication.

Release form and composition

The dosage form is represented by 1.5 ml ampoules of No. 3, 5 per pack. Injection solution has a yellow-green color. Dosage 1 ampoule is:
    Meloxicam - 15 mg.
The production of this medicinal product is owned by Boehringer Ingelheim Espana (Spain).

Indications for use

In the form of injection solution, Movalis is used to relieve combat syndrome and short-term relief of symptoms in rheumatoid arthritis, ankylosing spondylitis, and osteoarthrosis.

Contraindications for injections Movalis

    hypersensitivity to the active component or other components;
    tendency to develop allergic reactions of immediate type after taking acetylsalicylic acid and its derivatives;
    ulcer / perforation of the stomach or intestines;
    granulomatous enteritis;
    ulcerative colitis;
    severe liver dysfunction;
    severe renal impairment;
    coagulation system diseases;
    bleeding from the digestive tract or cerebrovascular disease;
    severe heart failure;
    During pregnancy and breastfeeding;
    children up to 18 years;
    removal of pain during coronary artery bypass surgery.
Care must be taken in the use of drugs for diseases of the digestive system, stagnation of the circulatory system, renal dysfunction, heart ischemia, pathologies of cerebral vessels and peripheral arteries, dyslipidemic or hyperlipidemic syndrome, diabetes mellitus, in old age, while smoking and abusing alcohol.
Care must be taken while taking anticoagulants, antiplatelet agents, oral glucocorticosteroids, some antidepressants, prolonged therapy with non-steroidal anti-inflammatory drugs.

Dosing and Administration

Movalis injection form is prescribed only for a quick (first 2-3 days) relief of pain and acute manifestations of diseases of the musculoskeletal system. Further treatment is carried out by applying the tablet form.
The daily dose, depending on the severity of pain and inflammation, can be from 7.5 to 15 mg. It is necessary to inject the medicine intramuscularly deeply, without mixing it with other drugs in a syringe.
In case of kidney dysfunction, the recommended therapeutic dose is 7.5 mg. Intravenous administration is prohibited.

Side effects of Movalis injections

    hematopoietic system: a decrease in the number of blood elements, changes in leukocyte formula, anemic syndrome;
    immune reactions: anaphylaxis, other manifestations of hypersensitivity type I;
    nervous disorders: headache, dizziness, tinnitus, drowsiness, impaired consciousness, emotional lability;
    digestive disorders: perforation of the walls, hemorrhages, ulcerative lesions of the stomach and duodenum, inflammation of the mucous membrane of the stomach, intestines, esophagus, mouth or liver, abdominal pain, dyspeptic symptoms, diarrhea, constipation, nausea, vomiting;
    skin manifestations: toxic necrolysis, angioedema, bullous dermatitis, erythema multiforme or exudative, pruritus, rash, urticaria, photosensitivity;
    respiratory system: bronchial asthma in the presence of allergy to nonsteroidal drugs;
    circulatory system: hypertension, tachycardia, hot flashes, edema;
    urinary system: kidney inflammation, nephrotic syndrome, kidney dysfunction, increased values ​​of renal parameters, dysuria;
    visual symptoms: conjunctivitis, visual disorders;
    local reactions: inflammation at the injection site.

special instructions

    Use of Movalis injections in pregnant or lactating breasts is contraindicated.
    In the presence of diseases of the digestive system, careful monitoring of this category of patients is necessary. In the case of the development of bleeding or the appearance of an ulcer, withdrawal of the funds is required. For older people, the effects of these side effects are more serious.
    With the use of this drug may increase in liver function or transaminases. Most often, it is insignificant and temporary. In the case of pronounced or prolonged changes, the use of Movalis injections should be discontinued, and observe the indicators.
    In debilitated or debilitated patients, side effects may increase, which is why they should be carefully monitored.
    Like other representatives of the group of nonsteroidal anti-inflammatory drugs, Movalis injections can mask the symptoms of the underlying infectious disease.
    A special category consists of patients who reported the occurrence of side effects from the skin and mucous membranes, the presence of hypersensitivity to Movalis injections. These negative manifestations usually occur in the first month of therapy and, as a rule, do not require withdrawal of funds.
    Meloxicam increases the risk of thrombosis, heart attack, angina with prolonged use, if there is a tendency to these pathologies, as well as with these diseases already suffered.
    Non-steroidal agents, in addition to inhibiting the synthesis of inflammatory mediators in the right place, also inhibit it in the kidneys, which can trigger the development of decompensation of latent form of renal failure. With the termination of the use of nonsteroidal kidney function is restored in full. Most often this phenomenon occurs in the elderly, as well as in patients with dehydration, stagnation of the circulatory system, cirrhosis of the liver, kidney pathologies, at the same time receiving diuretics, and undergoing complex operations that lead to hypovolemia. Before the appointment of Movalis to this group of patients, monitoring of diuresis and renal functions is required. The combined intake of nonsteroids and diuretics can provoke the retention of sodium, potassium and water ions, as well as a decrease in the excretion of sodium when taking diuretics. This may increase the signs of heart failure or hypertension in patients prone to these pathologies. Therefore, this category also requires careful monitoring of the condition, adequate hydration and the study of the functional ability of the kidneys.
    Meloxicam can affect the ability to conceive, with the result that it is not recommended for women who have problems in this area. When examining the reproductive function of such a woman, the use of Movalis injections should be discontinued.
    Studies on the safety of meloxicam while driving a vehicle or performing work requiring increased attention have not been conducted. However, when performing these actions, you should consider the possibility of dizziness, drowsiness and other disorders of the nervous system.

Drug interactions

    other agents that inhibit the synthesis of prostaglandins, in combination with meloxicam, increase the risk of ulcerogenic action and bleeding from the digestive tract, with the result that their combination is undesirable;
    antidepressants from the group of serotonin uptake inhibitors may also increase the risk of bleeding;
    with a combination of nonsteroidal agents with lithium preparations, there is an increase in the lithium content in the blood due to a decrease in its excretion. In this case, it is necessary to monitor the concentration of lithium in the application of meloxicam, change the dosage regimen and cancel;
    nonsteroidal anti-inflammatory drugs can increase the blood concentration and hematological toxicity of methotrexate. Therefore, the use of methotrexate and meloxicam at a dosage of more than 15 mg per week is undesirable;
    when taking non-steroidal drugs, the effect of intrauterine contraceptive devices is reduced;
    with the simultaneous use of nonsteroids and diuretic drugs in the case of dehydration may develop kidney failure;
    nonsteroidal drugs cause a weakening of the vasodilating effect of antihypertensive drugs as a result of inhibition of prostaglandin synthesis;
    nonsteroidal drugs and antagonists of type 2 angiotensin receptors cause a decrease in glomerular filtration, which can threaten the occurrence of renal failure. With this combination of drugs requires regular monitoring of kidney activity;
    with the combination of nonsteroids with cyclosporine, it is possible to enhance its toxic effect on the kidneys;
    possible manifestation of the interaction of meloxicam with inhibitors of hepatic enzymes or their substrates;
    There is the possibility of the interaction of meloxicam with oral hypoglycemic agents.

Terms and conditions of storage

Movalis injections must be protected from exposure to sunlight and access of children. Storage temperature range - not higher than 30 degrees. Shelf life - 5 years.

Terms of sell

You don't need a prescription to buy Movalis injections.